Showing results (281-290 of 4,510) with videos related to

Sort By:
Pageof 451
Future Oncology (London, England)|November 29, 2017
Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?Alessandra Fabi, Diana Giannarelli, Luca Moscetti, et al.
Future Oncology (London, England)|December 1, 2017
Dissecting the heterogeneity of stage III non-small-cell lung cancer through incorporation of grade and histologyOmar Abdel-Rahman
Future Oncology (London, England)|February 10, 2018
A multiparametric analysis combining DCE-MRI- and IVIM -derived parameters to improve differentiation of parotid tumors: a pilot studyFrancesca Patella, Giuseppe Franceschelli, Mario Petrillo, et al.
Future Oncology (London, England)|December 1, 2018
Demystifying biosimilars: development, regulation and clinical useHope S Rugo, Robert M Rifkin, Paul Declerck, et al.
Future Oncology (London, England)|December 8, 2018
Skin adverse events in recently approved targeted therapies in solid malignanciesMaya Habre, Antoine Salloum, Samer Bassilios Habre, et al.
Future Oncology (London, England)|November 23, 2019
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinibJohn Nemunaitis, Sebastian Bauer, Jean-Yves Blay, et al.
Future Oncology (London, England)|November 12, 2019
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective studyJack R Gallagher, Kylee Jean Heap, Susan Carroll, et al.
Future Oncology (London, England)|November 14, 2019
Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseasesWojciech Jurczak, Stanley Cohen, Timothy M Illidge, et al.
Future Oncology (London, England)|November 28, 2019
Analysis of TGCA data reveals genetic and epigenetic changes and biological function of MUC family genes in colorectal cancerZhipeng Jiang, Huashe Wang, Liang Li, et al.
Future Oncology (London, England)|November 21, 2019
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancerCarolyn E Haunschild, Krishnansu S Tewari
Pageof 451